Full Text Journal Articles in
Journal Drugs Aging

Advertisement

Find full text journal articles






Persistence of Effect of Medication Review on Potentially Inappropriate Prescriptions in Older Patients Following Hospital Discharge.

Camille Debacq, Julie Bourgueil, Amal Aidoud, Joëlle Bleuet, Marc Mennecart, Veronique Dardaine-Giraud, Bertrand Fougère,

<h4>Background</h4>Potentially inappropriate prescriptions (PIPs) can lead to adverse drug reactions and should be avoided whenever possible.<h4>Objective</h4>Our objective was to assess the PIP resumption rate 6 months after discharge from our geriatric unit and to compare it with data in the literature.<h4>Methods</h4>This single-center observational study included patients aged ≥ 70 years with at least one ... Read more >>

Drugs Aging (Drugs & aging)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study.

Susann Varano, David Staskin, Jeffrey Frankel, Denise Shortino, Rachael Jankowich, Paul N Mudd,

<h4>Background</h4>Overactive bladder (OAB) is common among older adults. The efficacy and safety of vibegron for the treatment of OAB were demonstrated in the international, phase III EMPOWUR trial. This subpopulation analysis from EMPOWUR assessed the efficacy and safety of vibegron in patients aged ≥ 65 and ≥ 75 years.<h4>Methods</h4>In EMPOWUR, ... Read more >>

Drugs Aging (Drugs & aging)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.

Margalida Calafat, Míriam Mañosa, Fiorella Cañete, Eugeni Domènech,

The number of older patients with inflammatory bowel disease (IBD) is increasing due to both improvements in the life expectancy of patients with long-lasting IBD and later onset of the disease. In spite of a less aggressive IBD phenotype, disease management in older patients is hampered by comorbidities and polypharmacy ... Read more >>

Drugs Aging (Drugs & aging)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Ethnic Variations in the Quality Use of Medicines in Older Adults: Māori and Non-Māori in Aotearoa New Zealand.

Joanna Hikaka, Rhys Jones, Carmel Hughes, Martin J Connolly, Nataly Martini,

In Aotearoa New Zealand (NZ), ethnic inequities in health outcomes exist. Non-Māori experience better access to healthcare than Māori, including access to the quality use of medicines. Quality medicines use requires that medicines provide maximal therapeutic benefit with minimal harm. As older adults are more at risk of harm from ... Read more >>

Drugs Aging (Drugs & aging)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Anticholinergic Burden Does Not Influence Delirium Subtype or the Delirium-Mortality Association in Hospitalized Older Adults: Results from a Prospective Cohort Study.

Mark James Rawle, Laura McCue, Elizabeth L Sampson, Daniel Davis, Victoria Vickerstaff,

<h4>Background</h4>Anticholinergic burden (ACB) is associated with an increased risk of delirium in the older population outside of the acute hospital setting. In acute settings, delirium is associated with increased mortality, and this association is greater with full syndromal delirium (FSD) than with subsyndromal delirium (SSD). Little is known about the ... Read more >>

Drugs Aging (Drugs & aging)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Removal of Drugs for Alzheimer's Disease from the List of Reimbursable Drugs in France: Analysis of Change in Drug Use, Disease Management and Cognition Using the National Alzheimer Data Bank (BNA).

Marie Herr, Joël Ankri, Capucine Diard, Anne Hiance-Delahaye,

<h4>Background</h4>Because of insufficient data about their benefit-risk ratio in real life, drugs used for Alzheimer's disease (AD; cholinesterase inhibitors and memantine) were withdrawn from the list of reimbursable drugs in France on 1 August 2018.<h4>Objectives</h4>In this context, this study aimed to investigate the effects of the removal of AD drugs ... Read more >>

Drugs Aging (Drugs & aging)
[2021, 38(1):63-74]

Cited: 0 times

View full text PDF listing >>



Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy.

Joon-Bom Kim, Eleonora M Lad,

Age-related macular degeneration (AMD) is a chronic, multifactorial disease and a leading cause of irreversible blindness in the elderly population in the Western Hemisphere. Among the two major subtypes of AMD, the prevalence of the nonneovascular (dry) type is approximately 85-90% and the neovascular (wet) type is 10-15%. Healthy lifestyle ... Read more >>

Drugs Aging (Drugs & aging)
[2021, 38(1):17-27]

Cited: 0 times

View full text PDF listing >>



Pharmacist Identification of Medication Therapy Problems Involving Cognition Among Older Adults Followed by a Home-Based Care Team.

Allison M P Levine, Erin E Emonds, Marie A Smith, Nathaniel M Rickles, George A Kuchel, David C Steffens, Alis Ohlheiser, Richard H Fortinsky,

<h4>Background</h4>Dementia, depression, and delirium alone or in combination (3Ds) can threaten independence among older adults, and polypharmacy may further accelerate decline. Clinical pharmacists can play an important role on multidisciplinary home-based care teams by identifying medication therapy problems (MTPs) involving cognition. Within a larger ongoing clinical trial, this paper describes ... Read more >>

Drugs Aging (Drugs & aging)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Treatment of Seizures in Older Patients with Dementia.

Benjamin Cretin,

The numbers of patients with dementia and patients with epilepsy are increasing in the global population. In fact, these two conditions are related, and it is estimated that at least 5-10% of seizures or epilepsy in older individuals (aged > 60 years) are caused by a neurodegenerative dementia. In the vast ... Read more >>

Drugs Aging (Drugs & aging)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Nurses', Pharmacists' and Family Physicians' Perceptions of Psychotropic Medication Monitoring in Australian Long-Term Care Facilities: A Qualitative Framework Analysis.

Aili V Langford, Garzee Tracy Ngo, Timothy F Chen, Chris Roberts, Carl R Schneider,

<h4>Background</h4>Current evidence suggests that despite modest benefit in using targeted psychotropic medications in the geriatric population, there is significant iatrogenic morbidity and mortality. Monitoring of the use of psychotropic medications by health care professionals (HCPs) to reduce adverse effects is often suboptimal; however, there have been few theoretically informed studies ... Read more >>

Drugs Aging (Drugs & aging)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Iterative Development of Clinician Guides to Support Deprescribing Decisions and Communication for Older Patients in Hospital: A Novel Methodology.

M H Duong, A J McLachlan, A A Bennett, N Jokanovic, D G Le Couteur, M T Baysari, D Gnjidic, F Blyth, S N Hilmer,

<h4>Background/objectives</h4>Medication review is an important component of the management of older hospital patients. Deprescribing (supervised withdrawal of inappropriate medicines) is one outcome of review. This study aimed to iteratively develop and test the usability of deprescribing guides, which support multidisciplinary clinicians to reduce inappropriate polypharmacy in older inpatients.<h4>Methods</h4>Deprescribing guides for ... Read more >>

Drugs Aging (Drugs & aging)
[2021, 38(1):75-87]

Cited: 0 times

View full text PDF listing >>



Acknowledgement to Referees : Acknowledgement to Referees.

Drugs Aging (Drugs & aging)
[2020, 37(12):859-861]

Cited: 0 times

View full text PDF listing >>



Short-Course Systemic and Topical Non-Steroidal Anti-Inflammatory Drugs: Impact on Adverse Renal Events in Older Adults with Co-Morbid Disease.

Cynthia Ciwei Lim, Andrew Teck Wee Ang, Hanis Bte Abdul Kadir, Puay Hoon Lee, Bandy Qiuling Goh, Sudha Harikrishnan, Jia Liang Kwek, Sheryl S W Gan, Jason Chon Jun Choo, Ngiap Chuan Tan,

<h4>Background</h4>Prolonged systemic non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with adverse renal outcomes among older adults. However, there is scant data regarding the renal safety of topical and short-course systemic NSAIDs. We aimed to evaluate the risk of acute adverse renal outcomes among older adults prescribed topical and short-term systemic ... Read more >>

Drugs Aging (Drugs & aging)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

Meital Oren-Shabtai, Noa Kremer, Moshe Lapidoth, Eran Sharon, Lihi Atzmony, Adi Nosrati, Emmilia Hodak, Daniel Mimouni, Assi Levi,

<h4>Background</h4>Bullous pemphigoid commonly affects older adults and has a detrimental effect on both quality of life and longevity. Systemic corticosteroids, the mainstay of therapy, may cause significant adverse effects, especially in older patients. Therefore, safer therapeutic options are being sought.<h4>Objective</h4>The objective of this article was to systematically review the published ... Read more >>

Drugs Aging (Drugs & aging)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study.

Raquel Freitas, Fátima Godinho, Nathalie Madeira, Bruno Miguel Fernandes, Flávio Costa, Mariana Santiago, Agna Neto, Soraia Azevedo, Maura Couto, Graça Sequeira, João Madruga Dias, Miguel Bernardes, Luís Miranda, Joaquim Polido Pereira, João Eurico Fonseca, Maria José Santos,

<h4>Background and objective</h4>The number of older patients with rheumatoid arthritis is increasing, but data on drug effectiveness and safety in these patients are scarce. This study assessed the effectiveness and safety of biologic disease-modifying antirheumatic drugs in older patients with rheumatoid arthritis.<h4>Methods</h4>This prospective cohort study was based on data recorded ... Read more >>

Drugs Aging (Drugs & aging)
[2020, 37(12):899-907]

Cited: 0 times

View full text PDF listing >>



Managing Nocturia in Frail Older Adults.

Dylan T Wolff, Kerry A Adler, Corey S Weinstein, Jeffrey P Weiss,

This review discusses the available evidence in the current evaluation and treatment of nocturia in frail older adults. No evidence specifically evaluates the use of behavioral interventions in the treatment of the frail older adult with nocturia, but their use is supported in other cohorts. Behavioral modifications and optimal management ... Read more >>

Drugs Aging (Drugs & aging)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Comment on: "Potentially Inappropriate Medications, Drug-Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?"

Enrico Brunetti, Gianluca Isaia, Mario Bo,

Drugs Aging (Drugs & aging)
[2021, 38(1):89-91]

Cited: 0 times

View full text PDF listing >>



Authors' Reply to Brunetti et al. "Potentially Inappropriate Medications, Drug-Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?"

Antonio De Vincentis, Claudio Pedone, Alessandro Nobili, Pier Mannuccio Mannucci, Raffaele Antonelli Incalzi,

Drugs Aging (Drugs & aging)
[2021, 38(1):93-94]

Cited: 0 times

View full text PDF listing >>



Decision Tools and Studies to Improve the Diagnosis of Urinary Tract Infection in Nursing Home Residents: A Narrative Review.

Joseph M Mylotte,

The overdiagnosis of urinary tract infection (UTI) in nursing home residents that results in unnecessary antibiotic treatment has been recognized for more than 2 decades. This has resulted in the publication of several decision tools for the diagnosis of UTI in nursing home residents. Given all of the decision tools ... Read more >>

Drugs Aging (Drugs & aging)
[2021, 38(1):29-41]

Cited: 0 times

View full text PDF listing >>



Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.

Dario Cattaneo, Luca Pasina, Aldo Pietro Maggioni, Andrea Giacomelli, Letizia Oreni, Alice Covizzi, Lucia Bradanini, Marco Schiuma, Spinello Antinori, Annalisa Ridolfo, Cristina Gervasoni,

<h4>Background</h4>Patients hospitalised with severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2; coronavirus 2019 disease (COVID-19)] infection are frequently older with co-morbidities and receiving polypharmacy, all of which are known risk factors for drug-drug interactions (DDIs). The pharmacological burden may be further aggravated by the addition of treatments for COVID-19.<h4>Objective</h4>The aim of ... Read more >>

Drugs Aging (Drugs & aging)
[2020, 37(12):925-933]

Cited: 0 times

View full text PDF listing >>



Safety of Pyrazinamide for the Treatment of Tuberculosis in Older Patients Over 75 Years of Age: A Retrospective Monocentric Cohort Study.

Stella Rousset, Margaux Lafaurie, Hélène Guet-Revillet, Caroline Protin, Jean Le Grusse, Hélène Derumeaux, Peggy Gandia, Fatemeh Nourhashemi, Laurent Sailler, Agnès Sommet, Pierre Delobel, Guillaume Martin-Blondel,

<h4>Objectives</h4>Pyrazinamide (PZA) has a controversial safety profile in older patients. We aimed to assess the frequency and risk factors for adverse drug reactions (ADRs) in patients over 75 years of age treated for tuberculosis with or without PZA.<h4>Methods</h4>We conducted a retrospective monocentric study including patients aged over 75 years treated for ... Read more >>

Drugs Aging (Drugs & aging)
[2021, 38(1):43-52]

Cited: 0 times

View full text PDF listing >>



Antipsychotics and Lorazepam During Delirium: Are We Harming Older Patients? A Real-Life Data Study.

Angelique Egberts, Hava Alan, Gijsbertus Ziere, Francesco U S Mattace-Raso,

<h4>Background</h4>Delirium affects approximately one out of three older hospitalized patients and is associated with poor clinical outcomes. Approaches used to manage delirium consist of non-pharmacological and pharmacological interventions. Antipsychotics and lorazepam are commonly used to treat symptoms of delirium, but conflicting data exist on the effect of these drugs on ... Read more >>

Drugs Aging (Drugs & aging)
[2021, 38(1):53-62]

Cited: 0 times

View full text PDF listing >>



Correction to: Romosozumab: A Review in Postmenopausal Osteoporosis.

Julia Paik, Lesley J Scott,

Unfortunately the sections were published incorrectly in the original article. ... Read more >>

Drugs Aging (Drugs & aging)
[2020, 37(11):857-858]

Cited: 0 times

View full text PDF listing >>



Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.

Greta Lozano-Ortega, David R Walker, Karissa Johnston, Alexis Mickle, Sean Harrigan, Basia Rogula, Rita M Kristy, John C Hairston, Carol R Schermer,

<h4>Background</h4>Cumulative exposure to one or more anticholinergic medications ("anticholinergic burden") is associated with an increased risk of adverse outcomes, particularly among older individuals. Mirabegron, an oral selective β3-adrenergic receptor agonist, has demonstrated efficacy in managing the symptoms of overactive bladder without contributing to anticholinergic burden. However, it is not known ... Read more >>

Drugs Aging (Drugs & aging)
[2020, 37(11):801-816]

Cited: 0 times

View full text PDF listing >>



Romosozumab: A Review in Postmenopausal Osteoporosis.

Julia Paik, Lesley J Scott,

Romosozumab (Evenity<sup>®</sup>), a humanized monoclonal antibody, promotes bone formation and inhibits bone resorption by inhibiting sclerostin, a protein involved in the regulation of bone formation. Subcutaneous romosozumab is approved in several countries, including those of the EU for treating severe osteoporosis as well as in the USA for osteoporosis in ... Read more >>

Drugs Aging (Drugs & aging)
[2020, 37(11):845-855]

Cited: 1 time

View full text PDF listing >>



Advertisement

Disclaimer
1.1037 s